Friday, 4 September 2026European Markets

CONTEXTVISION And VIRBAC Have A High Dividend Yield And Return On Equity In The Healthcare Sector.

Loading stream...

(vianews) - contextvision (contx.ol) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.

financial asset price forward dividend yield return on equity
contextvision (contx.ol) kr6.66 3.46% 61.1%
virbac (virp.pa) €346.00 0.39% 13.85%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. contextvision (contx.ol)

3.46% forward dividend yield and 61.1% return on equity

contextvision ab (publ), a medical technology software company, provides image analysis and imaging for medical systems in asia, europe, and the united states. the company offers image enhancement software for 2d/3d/4d ultrasound, radiography, magnetic resonance imaging (mri), and veterinary. its products include rivent that offers unparalleled image quality for various types of ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; rivent mobile, an enhancing ultrasound image for the handheld ultrasound devices using mobile phones and tablets; and rivent 3d, an image enhancement product for 3d ultrasound. the company also provides altumira/altumira plus, a platform for digital radiography; and orthopedic package for orthopedic imaging. in addition, it offers gopview mri2plus, an image enhancement solution for mri. the company was founded in 1983 and is headquartered in stockholm, sweden.

earnings per share

as for profitability, contextvision has a trailing twelve months eps of kr0.47.

pe ratio

contextvision has a trailing twelve months price to earnings ratio of 14.17. meaning, the purchaser of the share is investing kr14.17 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 61.1%.

volatility

contextvision's last week, last month's, and last quarter's current intraday variation average was a negative 0.45%, a negative 0.01%, and a positive 2.34%.

contextvision's highest amplitude of average volatility was 2.92% (last week), 2.42% (last month), and 2.34% (last quarter).

dividend yield

as maintained by morningstar, inc., the next dividend payment is on nov 2, 2023, the estimated forward annual dividend rate is 0.3 and the estimated forward annual dividend yield is 3.46%.

sales growth

contextvision's sales growth for the current quarter is 29.8%.

more news about contextvision.

2. virbac (virp.pa)

0.39% forward dividend yield and 13.85% return on equity

virbac sa manufactures and sells a range of products and services for companion animals and farm animals in france, europe, latin america, north america, asia, pacific, and africa and the middle east. the company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. it serves veterinarians, farmers, and pet owners. virbac sa was founded in 1968 and is headquartered in carros, france.

earnings per share

as for profitability, virbac has a trailing twelve months eps of €14.12.

pe ratio

virbac has a trailing twelve months price to earnings ratio of 24.5. meaning, the purchaser of the share is investing €24.5 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.85%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, virbac's stock is considered to be oversold (<=20).

more news about virbac.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com